To investigate the efficacy of endoscopic ablation of Hunner lesions (HLs) in patients with interstitial cystitis (IC) and to find predictors of early recurrence of HLs.
Introduction
Interstitial cystitis (IC) is a chronic condition characterised by hypersensitive bladder symptoms and bladder pathology (Hunner lesion [HL] or mucosal bleeding after distension) after excluding other diseases-explaining symptoms [1] . Hypersensitive symptoms are pain, discomfort, or pressure in the bladder associated with urinary frequency, urgency, and nocturia. IC is commonly categorised into an ulcerative form with HLs and a non-ulcerative form.
Since the first report of endoscopic treatment of the ulcerative form by Kerr [2] in 1971, several studies have examined its effectiveness as a treatment option. Recent studies have reported efficacy and continued pain relief for months to 2 years after treatment. The recent AUA guidelines recommend that, if HLs are present, fulguration (with laser or electrocautery) and/or injection of triamcinolone should be performed [3] . Although most patients undergo electrocoagulation or fulguration, re-operation might be necessary due to recurrence of symptoms. However, despite these studies and guidelines, most studies on endoscopic ablation as a treatment for IC have used discordant treatment methods and have been retrospective in nature. Furthermore, predictive factors associated with early recurrence have not been determined [2, [4] [5] [6] [7] [8] [9] [10] .
In the present study, we evaluated the efficacy of endoscopic ablation of HLs in patients with IC and the characteristics of HLs based on a long-term follow-up. We also investigated predictors of recurrence of HLs.
Patients and Methods
This was a prospective study conducted at a single centre between November 2012 and March 2017, and approved by the Institutional Review Board of our hospital. Before treatment, all patients completed a 3-day voiding diary, cystoscopic examination, and baseline questionnaires in the screening period. Inclusion criteria included adult patients aged >20 years who were diagnosed with HL type IC on cystoscopic examination and whose symptoms persisted for >6 months. At cystoscopy, a circumscribed, reddened mucosal area with small vessels radiating towards a central scar in the bladder (Fig. 1 ) was diagnosed as a HL. Symptoms were evaluated using several indices. Patients with an O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI) of ≥12, Pelvic Pain and Urgency/ Frequency (PUF) Patient Symptom Scale score of ≥13, and visual analogue scale (VAS) pain score of ≥4 were included in the study. All patients who previously underwent ablation in other hospitals were excluded from the study.
All enrolled patients with IC underwent endoscopic ablation by a single surgeon. In all cases, we performed transurethral resection (TUR) and/or coagulation with a bipolar loop under spinal or general anaesthesia. During TUR of the HLs, deep resection with a cutting current was performed to include about half of the detrusor muscle layer. Transurethral coagulation was conducted to coagulate only the HLs (Fig. 1) . All pathological results for the resected tissues were reported routinely. Bleeders were treated by direct pinpoint coagulation. After the procedure, all patients received pentosan polysulphate sodium 100 mg three-times daily and amitriptyline 2.5 mg once daily to prevent recurrence and relieve symptoms.
Follow-up was performed at 1, 3, 6, 9, and 12 months after surgery. After 12 months, patients were advised to schedule a visit whenever they experienced uncomfortable symptoms. Cystoscopic examination was performed every 6 months or as symptoms necessitated. Recurrence included both recurrence at the previous ablation site and new lesions elsewhere in the bladder mucosa. Questionnaires were administered and 3-day voiding diaries were assessed at each visit after the first operation. Symptom questionnaires and 3-day voiding diaries up to the time of recurrence were assessed in patients with recurrence, while these items were analysed until 12 months 
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© 2017 The Authors BJU International © 2017 BJU International in those patients without recurrence. We repeated endoscopic ablation when HLs recurred on cystoscopy and when symptoms were aggravated during the follow-up period. We defined early recurrence as recurrence at ≤12 months and late recurrence as >12 months after initial ablation.
The primary outcome was recurrence-free survival time after ablation treatment. Secondary outcomes were changes in mean number of daytime frequency, nocturia, and urgency episodes and indices including ICSI, ICPI, PUF, and VAS pain score. We also analysed factors predictive of early recurrence. Adverse events (AEs) were assessed throughout the study.
All data analyses were performed using the Statistical Package for the Social Sciences (SPSS â Statistics version 23; SPSS Inc., IBM Corp., Chicago, IL, USA). Descriptive statistics were used to evaluate patient characteristics. Patient-reported outcomes were analysed with the use of Fisher's exact test for categorical outcomes or a t-test for continuous measures. The KaplanMeier method was applied to evaluate recurrence-free time. A multivariable analysis was performed using a Cox regression model to assess predictors of early recurrence. All tests were two-sided, and statistical significance was set at P < 0.05.
Results
We enrolled 91 patients, of whom 17 were lost to follow-up, one underwent concurrent transurethral incision of prostate and one was diagnosed with bladder cancer. Finally, 72 patients were analysed. The female-to-male ratio was 3.5:1, and the mean (SD) patient age was 62.6 (9.7) years. The median (range) follow-up period was 29.5 (12.0-50.0) months. On cystoscopic examination, 16.7% (n = 12) of patients had a single HL, whilst 83.3% (n = 60) of the patients had more than two HLs (Table 1) .
Recurrence-free Survival and Factors Predictive of Early Recurrence
After primary ablation treatment, HLs recurred in 75.0% (54/72) of patients with a median (SD) recurrence-free time of 12.0 (1.6) months. Of the 54 patients in whom HLs recurred, 64.8% (n = 32) had new HLs at sites other than the previous ablation site, 18.5% (n = 10) had HLs surrounding the site of the previously ablated lesion, and 22.2% (n = 12) had recurrences at both sites. In all, 50 of these 54 patients underwent a second ablation treatment. Recurrence occurred in 44.0% (22/50) after the second operation, with a median (SD) recurrence-free time of 18.0 (5.1) months. Although recurrence-free time appeared to be prolonged after the second round of ablation compared to the first round, this difference was not statistically significant (P = 0.153; Fig. 2 ).
In all, 28 patients (38.9%) had HL recurrence at ≤12 months of the primary ablation. In these patients, maximum cystometric capacity (MCC) was significantly lower than in patients that had recurrence at >12 months after the primary ablation or those who did not experience recurrence, at a mean (SD) of 216.6 (87.6) vs 277.0 (96.9) mL (P = 0.009; Table 2 ). In multivariable analysis, lower MCC [odds ratio (OR) 1.01, 95% CI 1.001-1.013; P = 0.017] was the only factor that predicted early recurrence. Sex, presence of previous hydrodistention (HD), and number of HLs did not affect early recurrence (Table 3) .
3-Day Voiding Diary and Questionnaires after Primary Ablation
The mean (SD) number of daytime frequency episodes decreased significantly from 13.9 (7.6) at baseline to the lowest level of 8.4 (3.3) at 1 month. Over the 12-month follow-up period, the number of daytime frequency episodes increased compared to immediately after primary ablation treatment; however, the reduction in daytime frequency episodes remained significant compared to baseline. The mean number of nocturia episodes decreased from a mean (SD) of 3.7 (2.5) at baseline to 2.0 (1.5) at 1 month, 2.1 (1.4) at 3 months, and 2.4 (1.5) at 6 months; these differences from baseline were all statistically significant. However, the reduction in number of nocturia events was not statistically significant after 9 months. At baseline, the mean (SD) number of urgency episodes per day was 12.7 (12.0), but this decreased to 3.3 (6.2) immediately after primary ablation and remained significantly lower at 12 months (Fig. 3) . The mean change in the VAS pain score was À3.28 at 1 month and À4.27 at 12 months after primary ablation. The VAS pain score showed a tendency to decrease continuously after surgery. PUF symptom and bother scores, ICSI, and ICPI showed the most improvement relative to baseline at 1 month after primary ablation treatment. The degree of improvement decreased gradually with follow-up; however, compared with baseline, these indices were all significantly better, even after 12 months (Fig. 3) .
3-Day Voiding Diary and Questionnaires after Secondary Ablation
After secondary endoscopic ablation, the mean number of daytime frequency, nocturia, and urgency episodes decreased to the lowest level at 3 months follow-up and gradually increased after 3 months. Improvements in the VAS pain score, PUF symptom and bother scores, ICSI, and ICPI after re-treatment for recurrent HLs were consistent with those seen after primary ablation treatment during the 12 months of follow-up (Fig. 4) .
Adverse Events
The most common AEs after endoscopic ablation treatment were haematuria (6.9%) and UTI (6.9%). Other AEs occurred in <3% of patients and were definitely not related to the ablation procedure.
Discussion
The present study investigated the therapeutic effect of endoscopic ablation of HL in patients with IC. The recurrence rate of HLs was 75.0% during the 30-month follow-up period and the median recurrence-free time was 12 months after primary ablation treatment. Of those patients in whom HLs recurred, 92.6% underwent repeat ablation treatment. Most previous studies have not been able to evaluate the exact recurrence rate because of limitations of retrospective studies. To compensate for this, previous retrospective studies mainly analysed the re-treatment rate or the mean time between primary and re-retreatment. Hillelsohn et al. [7] reported that 45.8% of their patients' required repeat fulguration and Chennamsetty et al. [5] reported that 69% of their patients underwent multiple electrocautery of HLs. The reason for the high recurrence rate of HL in our present study is the result of being a prospective observational study with regular cystoscopic examinations. Thus, our present results of recurrence rates and recurrencefree survival times after ablation treatment of patients with HL type IC are more reflective of clinical reality.
There were no predictive factors related to overall recurrence; however, early recurrence was associated with a preoperative small bladder capacity. In patients with a normal bladder capacity, even if HLs recur, the symptoms may not be severe, and repeat ablation can be delayed. In patients with a small bladder capacity, if HLs develop, the symptoms can be more severe, necessitating early repeat ablation treatment. Thus, in patients with small bladder capacity, it may be necessary to fully explain that early symptomatic deterioration may occur after ablation. The number of HLs and other factors at the time of initial diagnosis were not related to early recurrence. Multiple ulcers were defined as two or more HLs on preoperative cystoscopy. The risk of recurrence in multiple HLs was expected to be higher than that in a single HL, but it emerged that the number of lesions did not affect recurrence.
For post-ablation therapy, pentosan polysulphate sodium 100 mg three-times daily and amitriptyline 2.5 mg once daily were prescribed to every patient. However, as the present study was not intended to investigate the difference in recurrence between patients with post-ablation medication and those without it, we could not determine what impact medication, as a post-ablation therapy, had on recurrence.
After a second ablation, the recurrence rate was 44.0% (22/50), and the median recurrence-free time was~18 months. The recurrence rate after re-operation was lower, and recurrence-free survival time was prolonged compared to those after the primary ablation. In other words, re-operation tended to reduce and delay recurrence. However, long-term follow-up is needed to determine whether repeat operations have a positive effect on IC remission. Whilst all recurred patients after the primary ablation underwent a second ablation treatment, 81.8% (18/22) of patients who had recurrence after the second ablation were able to undergo tertiary endoscopic ablation. The remaining 18.2% of patients required augmentation cystoplasty because the HLs were too wide to ablate or the initial bladder capacity was small. They had a high risk of recurrence as complete ablation was difficult due to the vast range of ulcerous lesions in the bladder, and the bladder capacity was small. This also corresponds to an analysis of the predictors of early recurrence. Our previous study also showed that refractory patients with HLs managed by augmentation cystoplasty with supratrigonal cystectomy resulted in favourable outcomes in most patients [11] .
However, the main purpose and therapeutic effect of endoscopic ablation is to preserve the bladder and alleviate the uncomfortable symptoms for patients, as well as to delay the need to perform major surgery such as augmentation cystoplasty. Kerr [2] performed a TUR in a female patient with HL in 1971 and reported symptom relief for 1 year. In 1974, Greenberg et al. [9] performed TUR in 28 of 77 patients with HLs, and all 28 patients showed improvement in symptoms. In 2000, Peeker et al. [10] reported that 40% of patients who underwent TUR of HLs had symptomatic improvement, the remission rate was 34.5%, and patients remained in remission for 3 years after the resection. In addition, Lee et al. [6] reported that combined hydrodistention and TUR treatment increased bladder capacity and reduced the frequency of micturition and pain. In all the above mentioned studies, TUR consistently improved symptoms. In the present study, symptom improvement was confirmed through a 3-day voiding diary and symptom questionnaires at every study visit. The number of frequency and urgency episodes, as well as all scores for the ICSI, ICPI, and PUF questionnaires were significantly improved immediately after the ablation. Symptoms deteriorated over time; however, compared with baseline, significant improvements were still seen after 12 months.
Ultimately, removal of HLs is a direct treatment method that improves symptoms. Although a clear mechanism has not been elucidated, Fall [12] suggested that TUR might remove intramural endings activated by the inflammatory process. We used a bipolar cutting loop to resect the mucosal layer including HLs or to coagulate the mucosa directly. The important point is that all HLs that can be identified must be removed and should be removed to the fullest extent possible. In this regard, a bipolar cutting loop is effective for fine resection. Nonetheless, ablation itself did not reduce the recurrence of HLs, and 64.8% of the patients had new HLs at remote sites other than the previous ablation site. Histopathologically, HL type IC has been reported to be characterised by pancystitis [13, 14] . Inflammatory cell infiltration such as an increase in plasma cells, urothelial denudation and expansion of clonal B-cells was observed in non-HL from random biopsy as well as in HL. Based on the above results, it is thought that the whole urothelium has a potential for developing HLs. Thus, in future there is a need for new treatments to prevent recurrence of HLs and symptoms.
To our knowledge, this is the first prospective observational study of endoscopic ablation to treat HLs in patients with IC. All patients recorded a voiding diary and answered standardised questionnaires, with periodic cystoscopy, providing objective information. However, our present study did have some limitations. We performed TUR or transurethral coagulation, but there was no analysis of whether the surgical procedure affected the outcome. In addition, no evaluation of bladder capacity was performed during the follow-up period, and it was not possible to confirm whether repeated operations affected bladder contracture. And, we evaluated the severity of HLs not by the area of distribution but just by the number. We cautiously expect that the results would have been different if there had been a way to describe the range of HLs clearly rather than the number of HLs. Thus, in further studies, we should consider the standardisation of how to describe the range of HLs.
Conclusions
Endoscopic ablation is an effective and safe treatment option for patients with HL type IC and significantly reduces pain and improves voiding symptoms. In addition, repeated ablation when symptoms worsen results in consistent improvement in symptoms and pain relief. The risk of early recurrence is relatively low except in patients with low bladder capacity. Therefore, repeat ablation upon every recurrence could help symptom control and bladder preservation if the bladder capacity of the patient is maintained.
